Harmony Biosciences Holdings, Inc. (HRMY) analyst actions
Rating and price-target actions on HRMY in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the HRMY overview →
5 measured HRMY analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion | Press release | -4.16% | +1.92% | |
| Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence | Press release | -1.12% | -1.71% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Reach Out | Press release | -0.02% | +1.61% | |
| Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs | Press release | +2.66% | +6.76% | |
| HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME | Press release | +0.17% | -3.09% |
Keep exploring
More HRMY: earnings → · SEC filings → · HRMY overview →